MD V did bring up one point that I found plausible

MD V did bring up one point that I found plausible -- that BP or other investment group would likely be interested in a hostile takeover of CYDY's executive team/BOD in order to exert their control. Like a corporate virus. Probably be easier and less costly than trying to do an outright buyout.

Changing subjects...

'Anecdotal' EIND results prove efficacy
Safety was already known from HIV, but proven again with ph2 m2m.

If those on this board are able to come to the obvious conclusion that the efficacy from m2m will be at worst outstanding, then I have no doubt that those working for BP have also come to the same conclusion.

Suppose leronlimab was a product of BP -- what do you think they would be doing with what is known about it thus far?

Now, again, if you're BP, what would you do with confirmation of efficacy? If I were a greedy mean unempathtic pig of a CEO, I would exert my influence on the FDA to require ph3 trial and use this delay as leverage for a better deal with CYDY knowing that an EUA will be given for s/c application.

So my advice, if NP were to ask (<-- I would be troubled if he were to ask!), would be to hold his nose and make a deal with the BP making the best offer. All we need is one to break ranks and join our side and the rest will trample over each other trying to be the next to cut a deal.